Marina Elena Cazzaniga

15PUBLICATIONS
66CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jan 27, 2026
Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review.

Khashayar Yazdanpanah Ardakani, Gaia Passarella, Andrea Gerardo Antonio Lania

|Jan 26, 2026
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

Giampaolo Bianchini, Luca Malorni, Roberta Caputo

|Jan 10, 2026
Metronomic 5-Fluorouracil and Vinorelbine Reduce Cancer Stemness and Modulate EZH2/NOTCH-1/STAT3 Signaling in Triple-Negative Breast Cancer Spheroids.

Alice Ilari, Emanuela Grassilli, Mario Mauri

|Nov 08, 2025
Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review.

Marina E Cazzaniga, Luis Costa, Gilles Freyer

|Jul 25, 2025
Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC).

Khashayar Yazdanpanah Ardakani, Francesca Fulvia Pepe, Serena Capici

|Sep 14, 2022
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic.

Selena Russo, Marco Bani, Marco Terraneo

Pageof 3

Frequent Collaborators

3 joint publications

Maria Grazia Cerrito

2 joint publications

Nicoletta Cordani

2 joint publications

Maria Rosaria Valerio

1 joint publications

Gaia Passarella